Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933 Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
Effects of CXCR2 antagonists on neutrophil chemotaxis from COPD patients Source: Annual Congress 2010 - Airway cells as targets for anti-inflammatory drugs Year: 2010
The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Elevated CCL2 responses in COPD and attenuation by selective chemokine receptor antagonists Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial Source: Eur Respir J 2015; 46: 1636-1644 Year: 2015
A CXCR2 antagonist inhibits polyI:C-induced airway neutrophil, but not lymphocyte infiltrate Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury Year: 2011
The purinergic receptor P2Y2 mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019
The expression of muscarinic receptors is involved in the p42/44ERK and NF-kB activation of human lung fibroblasts from COPD subjects Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Neutrophils and neutrophil chemokine receptor (CXCR1 and 2) gene expression in severe exacerbations of COPD and asthma Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
LSC 2011 Abstract: P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil accumulation during lung inflammation Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Endobronchial biopsy neutrophilia, IL-8, ENA-78 and neutrophil chemokine receptor (CXCR1 & CXCR2) gene expression in severe exacerbations of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 377s Year: 2002
Toll-like receptor stimulation induces airway hyperresponsiveness to bradykinin, an effect mediated by JNK and NF-κB signaling pathways Source: Eur Respir J 2005; 26: Suppl. 49, 732s Year: 2005